Drug Profile
Research programme: PARP-inhibitors - Allarity Therapeutics
Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Unknown
- Developer Allarity Therapeutics
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Breast cancer in USA (unspecified route) (Allarity Therapeutics pipeline, October 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 26 Jun 2018 2X Oncology is now called Oncology Venture US